Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

Table 2 Incidence of neuropathy in metformin user and non-user group

				Propensity score-matched1
	Metformin user, n (%)	Metformin non-user, n (%)	P value	Metformin user, n (%)	Metformin non-user, n (%)	P value
2016
Neuropathy incidence	914/30683 (2.98)	158/3922 (4.03)	0.0004	49/3922 (1.25)	158/3922 (4.03)	< 0.0001
2017
Neuropathy incidence	959/31624 (3.03)	143/4004 (3.57)	0.0635	64/4004 (1.60)	143/4004 (3.57)	< 0.0001

¹Propensity score-matching was performed by including baseline age, gender, and comorbidities (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular accident or transient ischemic attack, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver disease, diabetes mellitus, hemiplegia, moderate to severe chronic kidney disease, solid tumor, leukemia, lymphoma, AIDS).